Sign up for the QMED & MD+DI Daily newsletter.
The new letter by FDA aimed to expand the recall notice to PCA pumps, which the original recall did not mention. It’s that gap in information that concerned FDA.
November 21, 2023
2 Min Read
Tuned_In / iStock via Getty Images
The Monoject syringes are part of Covidien’s portfolio that Cardinal brought from Medtronic for $6.1 billion in 2017. In June of this year, they changed the text on the syringes, branding it under Cardinal, which changed the dosing dimensions.
It was the difference of dimensions that initially sparked the recall after it was reported to affect use with syringe pumps, potentially resulting in pump performance issues like overdose, underdose, delay in therapy, and delay in occlusion alarms.
The new notice published by FDA, titled “Do Not Use Cardinal Health Monoject Syringes with Syringe Pumps and PCA Pumps” aimed to expand the notice to PCA pumps, which the original recall did not mention. FDA said that it’s that gap in information which concerned them. “The FDA has concerns that the information provided by Cardinal Health has not sufficiently mitigated the risk of incompatibility when Cardinal Health Monoject syringes are used with other pumps, specifically PCA pumps,” the agency wrote.
Along with the agency’s advice not to use the recalled syringes with PCA pumps, it also updated its recommendations regarding the use of older Coviden Monoject syringes.
“Do not use Cardinal Health Monoject syringes with syringe pumps or PCA pumps,” FDA wrote. “You may continue to use Covidien Monoject syringes with syringe pumps or PCA pumps. Be aware that both brands of syringes state only ‘monoject’ on the syringe itself and do not include the company name. Keep the outer packaging with the Covidien Monoject syringe prior to using it with a syringe pump or PCA pump in order for end-users to verify that the syringe can be used.”
FDA noted it also had concerns that the incompatibility of the syringes could apply to additional sizes not listed in the recall and said officials are working with the manufacturer to address these questions.
About the Author(s)
Managing Editor, MD+DI
Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].
You May Also Like
BioSig Cuts a Substantial Number of PositionsFeb 20, 2024|2 Min Read
Philips BrightView Imaging System Hit with Class I RecallFeb 20, 2024|2 Min Read
Medtronic Exits Ventilator Market, Raises FY24 OutlookFeb 20, 2024|4 Min Read
Medical Device Suppliers Unite to Form the WCDAFeb 20, 2024